GlassScriptPhysician profile
Lily Chin
NPI 1497069009
$11,479.12
in general payments reported to CMS, 2019-2025
26 companies · $3,175 in 2025
The $3,175 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $1,407 · 2021: $664 · 2022: $1,387 · 2023: $820 · 2024: $2,060 · 2025: $3,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,356 · Consulting Fee: $1,673 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.54 |
| Consulting Fee | $1,673.32 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $2,277.87 | 2019-2023 | Flarex |
| Rxsight INC | $2,012.09 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Allergan, INC. | $1,486.84 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $892.83 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Alcon Vision LLC | $891.74 | 2022-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Sun Pharmaceutical Industries INC. | $616.33 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $466.20 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $379.89 | 2023-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $359.65 | 2019-2021 | |
| Glaukos Corporation | $266.78 | 2019-2024 | Photrexa |
| Dompe US, INC. | $239.46 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $213.56 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $201.10 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $169.01 | 2024-2025 | Acuvue |
| Oyster Point Pharma, INC. | $152.86 | 2023-2024 | Tyrvaya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $147.61 | 2019-2021 | |
| Shire North American Group INC | $144.28 | 2019 | |
| Amgen INC. | $143.72 | 2020-2025 | Tepezza |
| Abbvie INC. | $107.96 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $104.09 | 2025 | Xdemvy |
| Genentech USA, INC. | $57.64 | 2023-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $54.30 | 2025 | Purified Cortrophin Gel, Iluvien |
| Apellis Pharmaceuticals, INC. | $27.55 | 2025 | Syfovre |
| Astellas Pharma US INC | $24.16 | 2024 | Izervay |
| Beaver-Visitec International, INC. | $20.90 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $20.70 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.